Literature DB >> 3552592

Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

K L Goa, E M Sorkin.   

Abstract

Nitrendipine is a calcium entry blocker shown to inhibit the movement of calcium through the 'slow channel' of cardiac and vascular smooth muscle, thus inducing peripheral vasodilation with consequent reductions in elevated blood pressure. As evidenced by clinical trials, nitrendipine promptly lowers blood pressure in patients with mild to moderate hypertension, and sustains this effect during long term administration. Combining nitrendipine with other antihypertensive agents such as diuretics or beta-blockers often results in successful treatment in patients unresponsive to nitrendipine monotherapy. Headache, oedema, flushing and palpitations commonly occurring during treatment with nitrendipine are generally mild, usually subsiding with continued therapy. Thus, although additional long term studies are required to properly assess the relative merits of the drug compared with other antihypertensives, by providing the clinician with an effective and safe alternative to traditional therapies, nitrendipine represents a step forward in the treatment of mild to moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552592     DOI: 10.2165/00003495-198733020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  96 in total

1.  Clinical experience with long-term nitrendipine treatment in essential hypertension.

Authors:  A Tourkantonis; A Lasaridis; L Settas
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

2.  Calcium-channel blockers and asthma.

Authors:  P J Barnes
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

3.  Calcium blockers and bronchoconstriction.

Authors:  C H Fanta; J M Drazen
Journal:  Am Rev Respir Dis       Date:  1983-06

4.  Role of calcium in arachidonic acid-induced contractions of guinea pig airways.

Authors:  M H Saad; J F Burka
Journal:  Eur J Pharmacol       Date:  1984-04-13       Impact factor: 4.432

5.  Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy.

Authors:  T C Fagan; C Sternleib; N Vlachakis; P C Deedwania; J L Mehta
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

6.  Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study.

Authors:  A K Jain; F G McMahon; J R Ryan; R Maronde; N Vlachakis; W Mroczek
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

7.  Nitrendipine kinetics in normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

8.  Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.

Authors:  F C Luft; G R Aronoff; R S Sloan; N S Fineberg; M H Weinberger
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

9.  Experience with nitrendipine--a new calcium antagonist--in hypertension.

Authors:  L Andrén; L Hansson; L Orö; T Ryman
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Factors involved in the antihypertensive action of calcium antagonists.

Authors:  B Garthoff; S Kazda; A Knorr; G Thomas
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

View more
  24 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.

Authors:  P A Soons; A G de Boer; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 6.  Grapefruit juice and drugs. How significant is the interaction?

Authors:  D G Bailey; J M Arnold; J D Spence
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

7.  Effect of activation on adhesion of flowing neutrophils to cultured endothelium: time course and inhibition by a calcium channel blocker (nitrendipine).

Authors:  I Perry; S M Buttrum; G B Nash
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.

Authors:  V Mast; C Fischer; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 10.  Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.

Authors:  M Asif A Siddiqui; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.